SOLIGENIX, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
SOLIGENIX, INC. (SNGX) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $973.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-03-31
- SOLIGENIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $973.00K, a 63.26% increase from fiscal 2024.
- SOLIGENIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $596.00K, a 41.57% increase from fiscal 2023.
- SOLIGENIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $421.00K, a 1.41% decline from fiscal 2022.
- SOLIGENIX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $427.00K, a 6.56% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|
| 2025-12-31 | $973.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $596.00K 10-K · filed 2025-03-21 |
| 2023-12-31 | $421.00K 10-K · filed 2024-03-15 |
| 2022-12-31 | $427.00K 10-K · filed 2023-03-31 |
| 2021-12-31 | $457.00K 10-K · filed 2022-03-29 |
| 2020-12-31 | $584.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |